Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 32 | 2021 | 775 | 4.650 |
Why?
|
| Developing Countries | 14 | 2021 | 106 | 3.300 |
Why?
|
| Pre-Exposure Prophylaxis | 10 | 2021 | 29 | 2.780 |
Why?
|
| Anti-HIV Agents | 12 | 2021 | 135 | 2.430 |
Why?
|
| Sexual Partners | 7 | 2021 | 105 | 1.260 |
Why?
|
| Condoms | 8 | 2019 | 67 | 0.900 |
Why?
|
| Health Promotion | 3 | 2017 | 407 | 0.860 |
Why?
|
| Counseling | 5 | 2015 | 279 | 0.770 |
Why?
|
| Sexual Behavior | 6 | 2021 | 179 | 0.710 |
Why?
|
| Risk Reduction Behavior | 5 | 2015 | 174 | 0.650 |
Why?
|
| Social Marketing | 2 | 2019 | 33 | 0.600 |
Why?
|
| Health Policy | 2 | 2017 | 221 | 0.530 |
Why?
|
| Sex Workers | 2 | 2017 | 9 | 0.480 |
Why?
|
| Contraception Behavior | 1 | 2013 | 17 | 0.470 |
Why?
|
| Family Planning Services | 1 | 2013 | 18 | 0.470 |
Why?
|
| AIDS Serodiagnosis | 1 | 2013 | 17 | 0.460 |
Why?
|
| Income | 3 | 2020 | 165 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2015 | 335 | 0.410 |
Why?
|
| Community Networks | 1 | 2012 | 96 | 0.410 |
Why?
|
| HIV Seropositivity | 2 | 2012 | 65 | 0.390 |
Why?
|
| Circumcision, Male | 2 | 2020 | 12 | 0.370 |
Why?
|
| Humans | 36 | 2021 | 68525 | 0.350 |
Why?
|
| Risk-Taking | 6 | 2017 | 210 | 0.300 |
Why?
|
| Miners | 2 | 2017 | 3 | 0.290 |
Why?
|
| Safe Sex | 4 | 2019 | 24 | 0.280 |
Why?
|
| Transients and Migrants | 2 | 2017 | 22 | 0.280 |
Why?
|
| Behavior Therapy | 2 | 2020 | 297 | 0.270 |
Why?
|
| Public Health | 2 | 2015 | 201 | 0.220 |
Why?
|
| Female | 17 | 2019 | 38015 | 0.200 |
Why?
|
| Male | 17 | 2020 | 37281 | 0.190 |
Why?
|
| Health Services | 1 | 2020 | 87 | 0.180 |
Why?
|
| Bias | 1 | 2019 | 148 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 929 | 0.150 |
Why?
|
| Chemoprevention | 1 | 2016 | 26 | 0.140 |
Why?
|
| Research Design | 1 | 2020 | 729 | 0.140 |
Why?
|
| Health Services Needs and Demand | 2 | 2014 | 149 | 0.140 |
Why?
|
| Health Education | 2 | 2009 | 279 | 0.130 |
Why?
|
| Truth Disclosure | 1 | 2015 | 48 | 0.130 |
Why?
|
| Program Evaluation | 2 | 2009 | 502 | 0.130 |
Why?
|
| Endemic Diseases | 1 | 2014 | 10 | 0.120 |
Why?
|
| Sex Education | 1 | 2014 | 20 | 0.120 |
Why?
|
| Vocational Education | 1 | 2013 | 4 | 0.120 |
Why?
|
| Women's Health Services | 1 | 2013 | 10 | 0.120 |
Why?
|
| Pregnancy Rate | 1 | 2013 | 14 | 0.120 |
Why?
|
| Africa | 1 | 2013 | 41 | 0.120 |
Why?
|
| Fertility | 1 | 2013 | 60 | 0.120 |
Why?
|
| Pregnancy | 4 | 2014 | 2331 | 0.120 |
Why?
|
| Risk Factors | 2 | 2021 | 5719 | 0.110 |
Why?
|
| Commerce | 1 | 2013 | 80 | 0.110 |
Why?
|
| Schools | 1 | 2014 | 156 | 0.110 |
Why?
|
| India | 1 | 2012 | 41 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2014 | 35 | 0.110 |
Why?
|
| Community Participation | 1 | 2012 | 42 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2015 | 310 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2014 | 92 | 0.100 |
Why?
|
| South Africa | 3 | 2020 | 45 | 0.100 |
Why?
|
| Health Planning | 1 | 2010 | 23 | 0.090 |
Why?
|
| Pandemics | 1 | 2014 | 346 | 0.090 |
Why?
|
| Behavioral Medicine | 1 | 2010 | 23 | 0.090 |
Why?
|
| Voluntary Programs | 2 | 2020 | 9 | 0.090 |
Why?
|
| Adult | 9 | 2020 | 21375 | 0.090 |
Why?
|
| Peer Group | 1 | 2009 | 104 | 0.080 |
Why?
|
| Young Adult | 5 | 2020 | 5708 | 0.080 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 25 | 0.080 |
Why?
|
| Adolescent | 5 | 2020 | 8903 | 0.080 |
Why?
|
| Mozambique | 2 | 2017 | 3 | 0.070 |
Why?
|
| Mass Media | 1 | 2006 | 29 | 0.070 |
Why?
|
| Tenofovir | 2 | 2016 | 10 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2009 | 766 | 0.070 |
Why?
|
| Tanzania | 2 | 2021 | 35 | 0.070 |
Why?
|
| Nevirapine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Syphilis, Congenital | 1 | 2004 | 5 | 0.060 |
Why?
|
| Social Support | 1 | 2007 | 423 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2004 | 117 | 0.060 |
Why?
|
| Health Behavior | 1 | 2006 | 458 | 0.050 |
Why?
|
| Compensation and Redress | 1 | 2020 | 8 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2020 | 24 | 0.050 |
Why?
|
| HIV | 1 | 2020 | 53 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2019 | 19 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 39 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 848 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2020 | 101 | 0.040 |
Why?
|
| Mass Screening | 1 | 2004 | 837 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 330 | 0.040 |
Why?
|
| Transgender Persons | 1 | 2017 | 15 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 1609 | 0.040 |
Why?
|
| Placebos | 1 | 2016 | 195 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 392 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2015 | 5 | 0.030 |
Why?
|
| Motivation | 1 | 2020 | 561 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 503 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Seasons | 1 | 2015 | 129 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 115 | 0.030 |
Why?
|
| Kenya | 2 | 2004 | 26 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2015 | 2453 | 0.030 |
Why?
|
| Health Personnel | 1 | 2017 | 286 | 0.030 |
Why?
|
| Infant | 2 | 2015 | 2891 | 0.030 |
Why?
|
| Financing, Organized | 1 | 2013 | 21 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 648 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2077 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 2004 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2264 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 955 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 21119 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 242 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2798 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 3185 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 880 | 0.020 |
Why?
|
| Botswana | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cote d'Ivoire | 1 | 2004 | 2 | 0.020 |
Why?
|
| Rwanda | 1 | 2004 | 3 | 0.020 |
Why?
|
| Zimbabwe | 1 | 2004 | 6 | 0.020 |
Why?
|
| Zambia | 1 | 2004 | 8 | 0.020 |
Why?
|
| Uganda | 1 | 2004 | 41 | 0.020 |
Why?
|
| Bolivia | 1 | 2004 | 3 | 0.020 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2004 | 6 | 0.020 |
Why?
|
| Child | 1 | 2015 | 6400 | 0.010 |
Why?
|
| Communication | 1 | 2006 | 329 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1582 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 581 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 14842 | 0.010 |
Why?
|